Q3 2025 · 13F-HR
Kynam Capital Management, LPholdings as filed
Filed 2025-11-14 · accession 0001907884-25-000002
$1.34B
Reported value
35
Positions
2025-09-30
Period end
The Brief · Kynam Capital Management, LP · Q3 2025
AI · grounded in 13F
Kynam Capital Management, LP initiated a new position in CLDX valued at $157.8M. The fund also established new stakes in SNDX for $131.1M and VERA for $117.0M. Additional new positions include COGT at $113.2M and PCVX at $110.6M. Total assets under management stand at $1.34B across 35 positions.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $157.8M | 11.8% | 6,100,729 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $131.1M | 9.76% | 8,520,000 | Common | SOLE |
| 92337R101 | VERA | VERA THERAPEUTICS INC | $117.0M | 8.71% | 4,027,800 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $113.2M | 8.43% | 7,886,172 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $110.6M | 8.24% | 3,071,588 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $95.6M | 7.11% | 4,427,927 | Common | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $80.8M | 6.01% | 2,005,205 | Common | SOLE |
| 09058V103 | BCRX | BIOCRYST PHARMACEUTICALS INC | $71.3M | 5.31% | 9,390,270 | Common | SOLE |
| 07373V105 | BEAM | BEAM THERAPEUTICS INC | $61.1M | 4.55% | 2,517,647 | Common | SOLE |
| 45258D105 | IMCR | IMMUNOCORE HLDGS PLC | $36.7M | 2.73% | 1,009,267 | Common | SOLE |
| 55287L101 | MBX | MBX BIOSCIENCES INC | $35.0M | 2.61% | 2,000,000 | Common | SOLE |
| 29286M105 | — | ENGENE HOLDINGS INC | $34.1M | 2.54% | 4,994,090 | Common | SOLE |
| Y95308105 | WVE | WAVE LIFE SCIENCES LTD | $33.4M | 2.49% | 4,560,053 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $32.6M | 2.43% | 2,329,998 | Common | SOLE |
| 89422G107 | TVTX | TRAVERE THERAPEUTICS INC | $22.7M | 1.69% | 949,727 | Common | SOLE |
| 268158201 | DVAX | DYNAVAX TECHNOLOGIES CORP | $21.3M | 1.59% | 2,145,319 | Common | SOLE |
| 67080M103 | NRIX | NURIX THERAPEUTICS INC | $20.0M | 1.49% | 2,168,605 | Common | SOLE |
| 91307C102 | UTHR | UNITED THERAPEUTICS CORP DEL | $20.0M | 1.49% | 67,588 | Common | SOLE |
| 03753U106 | APLSUSD | APELLIS PHARMACEUTICALS INC | $18.3M | 1.36% | 808,607 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $16.8M | 1.25% | 675,000 | Common | SOLE |
| 75943R102 | RLAY | RELAY THERAPEUTICS INC | $15.1M | 1.12% | 2,887,014 | Common | SOLE |
| 230031106 | CGEM | CULLINAN THERAPEUTICS INC | $13.7M | 1.02% | 2,302,172 | Common | SOLE |
| 23284F105 | CTMX | CYTOMX THERAPEUTICS INC | $11.6M | 0.87% | 3,646,503 | Common | SOLE |
| 023111404 | AMRN | AMARIN CORP PLC | $9.4M | 0.70% | 576,111 | Common | SOLE |
| 12233L206 | BNR | BURNING ROCK BIOTECH LTD | $8.6M | 0.64% | 994,883 | Common | SOLE |
| 25056L103 | DSGN | DESIGN THERAPEUTICS INC | $7.8M | 0.58% | 1,029,579 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $7.4M | 0.55% | 606,171 | Common | SOLE |
| 46333X108 | IRWD | IRONWOOD PHARMACEUTICALS INC | $7.2M | 0.53% | 5,466,825 | Common | SOLE |
| 142038108 | CRBU | CARIBOU BIOSCIENCES INC | $7.1M | 0.53% | 3,067,774 | Common | SOLE |
| M96088105 | URGN | UROGEN PHARMA LTD | $6.9M | 0.52% | 282,412 | Common | SOLE |
| 374163103 | GERN | GERON CORP | $4.7M | 0.35% | 3,456,318 | Common | SOLE |
| 869367102 | STRO | SUTRO BIOPHARMA INC | $4.4M | 0.33% | 5,088,099 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $4.1M | 0.31% | 253,979 | Common | SOLE |
| N71542109 | PRQR | PROQR THRAPEUTICS N V | $3.5M | 0.26% | 1,649,462 | Common | SOLE |
| 28658R106 | CLYM | CLIMB BIO INC | $2.1M | 0.15% | 1,028,341 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.